<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>521-TOPIRAMATE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TOPIRAMATE" rxcui="38404">
<ATC code="N03AX11" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the concentrations of the topiramate with risk of lower effectiveness, due to increase of its hepatic metabolism by the carbamazepine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, and if needed, adjustment of the dosage of the toprimate during the treatment with the carbamazepine and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>521-TOPIRAMATE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TOPIRAMATE" rxcui="38404">
<ATC code="N03AX11" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES" code="G03AB-001" /></DRUG2>
<DESCRIPTION>For doses of topiramate &gt;= 200 mg/day: Risk of decrease of the contraceptive effectiveness due to decrease of the concentrations of estrogen</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Another method of contraception, in particular a barrier type, should be used. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>521-TOPIRAMATE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TOPIRAMATE" rxcui="38404">
<ATC code="N03AX11" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG2>
<DESCRIPTION>For doses of topiramate &gt;=200mg/day: increase of the the plasma concentrations of lithium that can reach toxic levels, with signs of overdose of lithium</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring. Adjustment of the dosage of lithium. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>521-TOPIRAMATE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TOPIRAMATE" rxcui="38404">
<ATC code="N03AX11" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="OXCARBAZEPINE" rxcui="32624">
<ATC code="N03AF02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the concentrations of the topiramate with risk of lower effectiveness, due to increase of its hepatic metabolism by the oxcarbazepine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, and if needed, adjustment of the dosage of the topiramate during the treatment with the oxcarbazepine and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>521-TOPIRAMATE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TOPIRAMATE" rxcui="38404">
<ATC code="N03AX11" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG2>
<DESCRIPTION>Increase of the hyperammonemia, with increased risk of encephalopathy </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring. </COMMENT>
</INTERACTION>
</INTERACTIONS>
